NDATOPICALGEL
Approved
Aug 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Clinical Trials (1)
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Started Dec 2023
10 enrolled
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Loss of Exclusivity
LOE Date
Jul 8, 2029
40 months away
Patent Expiry
Jul 8, 2029
Company
Helsinn
Ireland - Dublin